Company Overview

Theralink Technologies, Inc. (“Theralink”) is a precision medicine and diagnostic testing company focused primarily on oncology. The company develops and commercializes protein-based and phosphoprotein-based assays intended to help physicians personalize cancer treatment decisions, particularly in breast cancer and other solid tumor indications. Public disclosures and company materials describe Theralink’s platform as combining molecular diagnostics, laboratory testing, and data analytics to identify signaling pathway activity and potential therapeutic targets.

The company’s principal revenue drivers have historically included laboratory-developed diagnostic testing services, biomarker analysis, and related precision oncology solutions offered to healthcare providers and biopharmaceutical stakeholders. Theralink operates within the broader molecular diagnostics and personalized medicine industries, serving oncologists, cancer centers, clinical researchers, and pharmaceutical partners. Its strategic positioning is tied to its focus on protein signaling analysis rather than solely genomic sequencing, which the company has presented as a differentiator in identifying active cancer pathways. Publicly available information indicates the company evolved from a diagnostic and translational medicine platform into a commercial precision oncology business through acquisitions, technology licensing, and laboratory expansion initiatives. Certain historical corporate development details vary across public disclosures, and some legacy ownership information remains inconclusive based on available public sources.

Business Operations

Theralink’s operations center on its diagnostic laboratory and precision oncology testing platform. The company has described its core activities as developing and processing assays that evaluate tumor biology using protein expression and phosphorylation analysis. Revenue generation has primarily been associated with clinical testing services, physician-ordered oncology assays, and collaborations involving biomarker research and therapeutic response analysis. Public filings indicate that the company’s activities are concentrated mainly in the United States, with limited evidence of large-scale international commercial operations.

The company’s operational assets include proprietary assay methodologies, laboratory infrastructure, and associated intellectual property related to protein signaling diagnostics. Theralink has also disclosed relationships with healthcare institutions, oncology providers, and pharmaceutical industry participants in support of validation studies and precision medicine initiatives. Publicly available information does not consistently identify large operating subsidiaries or material joint ventures, and several partnership arrangements referenced in company communications have limited independently verifiable detail. Data regarding the scale and financial contribution of individual partnerships is inconclusive based on available public sources.

Strategic Position & Investments

Theralink’s strategic direction has emphasized expanding adoption of precision oncology diagnostics and increasing the clinical utility of its protein-based testing platform. Company disclosures have referenced growth initiatives focused on broader physician adoption, reimbursement expansion, clinical evidence generation, and integration of laboratory data into treatment decision workflows. The company has also highlighted efforts to participate in the evolving personalized medicine ecosystem, where companion diagnostics and biomarker-driven therapies continue to gain importance across oncology markets.

Public materials indicate that Theralink has pursued investment in laboratory capabilities, assay validation, and commercial expansion rather than large-scale diversified acquisitions. The company has also discussed opportunities involving artificial intelligence-enabled analytics and data-driven treatment selection, although the extent of commercial deployment remains limited in publicly verifiable sources. While Theralink has referenced strategic collaborations and technology expansion efforts, publicly available filings do not indicate ownership of a broad portfolio of subsidiaries or major non-core investments comparable to larger diagnostics companies.

Geographic Footprint

Theralink is headquartered in the United States, and its operations appear to be primarily concentrated within the domestic healthcare and oncology diagnostics market. Public filings and corporate disclosures identify the company’s principal commercial focus as serving U.S.-based oncologists, healthcare systems, and cancer treatment providers. The company’s laboratory and operational infrastructure are likewise centered in the U.S.

Although Theralink’s technology and research activities may have relevance to international oncology markets, available public information does not demonstrate a significant direct operating presence across multiple continents. There is limited evidence of substantial foreign subsidiaries, manufacturing operations, or international revenue concentration. Any broader global influence appears to stem more from participation in the international precision medicine and oncology research landscape than from extensive overseas commercial infrastructure.

Leadership & Governance

Theralink’s leadership structure reflects its focus on diagnostics commercialization, oncology research, and healthcare technology development. Public disclosures indicate that executive leadership has emphasized precision medicine adoption, clinical validation, and the expansion of protein-based diagnostic applications in oncology care. Governance and strategic oversight have been shaped by executives and board members with backgrounds in healthcare, diagnostics, biotechnology, and finance.

Key executives identified in public company disclosures include:

• Faith Zaslavsky, Ph.D. – Chief Executive Officer
• Richard “Rick” Bowling – Chief Financial Officer
• Michael T. McGarry – Chairman of the Board

Certain executive and board compositions have changed over time according to public filings, and some historical leadership records differ across corporate announcements and regulatory disclosures. Current governance details should therefore be confirmed against the company’s most recent public filings and corporate communications.